Hostname: page-component-cc8bf7c57-5wl6q Total loading time: 0 Render date: 2024-12-10T05:34:55.763Z Has data issue: false hasContentIssue false
  • English
  • Français

Litigation on Third Party Prescription Programs: An Update

Published online by Cambridge University Press:  28 April 2021

Richard R. Abood
Get access Rights & Permissions [Opens in a new window]

Extract

The American health care system is currently engaged in one of the most profound transitions in recent history. Demands for cost containment propel this transition, catalyzed by third party payers—federal and state governments, Blue Cross/Blue Shield, private insurers, third party administrators, and employers. The era of usual and customary compensation for health care providers participating in third party programs may be rapidly ending. Pharmacy witnessed the demise of usual and customary compensation in the early 1960s and has been fighting to regain it since then.

In recent years, third party prescription programs (TPPPs) have been the subject of, or have been affected by, various lawsuits, rulings by the Federal Trade Commission (FTC), and state attorney general opinions. Most have not been favorable for pharmacists. In a previous article in Law, Medicine & Health Care, this author explored some of the litigation and legislation which pharmacists attempted as a means to solve the problems presented by TPPPs.

Type
Article
Information
Law, Medicine and Healthcare , Volume 13 , Issue 2 , April 1985 , pp. 75 - 81
Copyright
Copyright © American Society of Law, Medicine and Ethics 1985

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abood, R., Pharmacists Challenge Third Party Prescription Programs: A Legal Analysis, Law, Medicine & Health Care 10(6): 257–61 (December 1982).Google Scholar
Pharmaceutical Card System, Inc. and PAID Prescriptions are the nation's largest claims processors. PCS includes over 50,000 member pharmacies and processes more than two million claims a month.Google Scholar
See Group Life and Health Ins. Co. v. Royal Drug Co., 440 U.S. 205, 209–10 (1979) (description of typical plan).Google Scholar
Abood, R.R.. Report on Third Party Prescription Programs (National Council of State Pharmaceutical Association Executives, Indianapolis, Ind.) (1984) at 1 [hereinafter referred to as NCSPAE Report].Google Scholar
Id.Google Scholar
40 Fed. Reg. 32,302 (1974) codified at 45 C.F.R. § 19.1 et seq.Google Scholar
45 C.F.R. § 19.5.Google Scholar
Id. § 19.3.Google Scholar
502 F. Supp. 1235, 1240–43 (D.C. Md. 1980). See also American Medical Ass'n v. Mathews, 429 F. Supp. 1179, 1194–97 (N.D. Ill. 1977).Google Scholar
See, e.g., Arkansas Pharmacists Ass'n v. Harris, 627 F.2d 867 (8th Cir. 1980).Google Scholar
Pennsylvania Pharmaceutical Ass'n v. Pennsylvania Department of Welfare, 542 F. Supp. 1349, 1352 (W.D. Pa. 1982).Google Scholar
Id. at 1354.Google Scholar
Id. at 1356.Google Scholar
Massachusetts Pharmaceutical Ass'n v. Rate Setting Commission, 438 N.E.2d 1072 (Mass. 1982).Google Scholar
Id. at 1076.Google Scholar
463 N.E.2d 1388 (Ind. App. 1984).Google Scholar
Id. at 1390.Google Scholar
587 F. Supp. 698 (S.D. Ohio 1984).Google Scholar
Id. at 710.Google Scholar
15 U.S.C. § 1 (1982).Google Scholar
Sausalito Pharmacy, Inc. v. Blue Shield of California, 677 F.2d 47 (9th Cir. 1982), cert. denied, 459 U.S. 1016 (1984); Medical Arts Pharmacy v. Blue Cross and Blue Shield, 675 F.2d 502 (2d Cir. 1982); Feldman v. Health Care Service Corp., 562 F. Supp. 941 (N.D. Ill. 1982); Royal Drug Co., Inc. v. Group Life and Health Ins. Co., 737 F.2d 1433 (5th Cir. 1984), cert. denied, 105 S.Ct. 912 (1985) [hereinafter referred to as Royal Drug].Google Scholar
15 U.S.C. §§ 1011–15 (1982).Google Scholar
440 U.S. 205, 217–30 (1979).Google Scholar
Continental T.V., Inc. v. GTE Sylvania, Inc. 433 U.S. 36 (1977).Google Scholar
See cases, supra note 21.Google Scholar
See Royal Drug, supra note 21, 1436–37 (horizontal agreements among competitors to fix prices could constitute a per se violation); Arizona v. Maricopa County Medical Soc'y, 457 U.S. 332, 348 (1982); United States v. Socony-Vacuum Oil Co., 310 U.S. 150, 223 (1940).Google Scholar
737 F.2d 1433 (5th Cir. 1984).Google Scholar
105 S.Ct. 912 (1985).Google Scholar
See Broadcast Music, Inc. v. Columbia Broadcast System, 441 U.S. 1, 16–24 (1979).Google Scholar
New Jersey Attorney General v. New Jersey Pharmaceutical Ass'n, 1981–2 Trade Cas. (CCH) ¶64,376 (N.J. 1981).Google Scholar
The West Virginia Pharmaceutical Association was subpoenaed by the antitrust division. See West Virginia Pharmacist 4: 1 (1980). See also New York v. Empire City Pharmaceutical Soc'y, Inc., No. 40789/78 (N.Y. Sup. Ct. 1978).Google Scholar
In re Michigan State Medical Soc'y, 48 Fed. Reg. 8997 (March 3, 1983) (FTC file #9129).Google Scholar
412 N.E.2d 129 (Ind. 1980).Google Scholar
Id. at 131.Google Scholar
Hinshaw Drug v. Blue Cross and Blue Shield, No. 82-29712CK (Ingham County Cir. Ct., Mich., December 6, 1983). See Michigan Pharmacist, p. 29 (May 1983) (report on filing of suit).Google Scholar
No. 76118 (Mich. App., 1984).Google Scholar
No. 78L-11257 (Cook County Cir. Ct., Ill., 1984).Google Scholar
See Illinois Pharmacists Association Newsletter 15: 2 (February 29, 1984).Google Scholar
Grettenberger Pharmacy, Inc. v. Blue Cross-Blue Shield of Michigan, 296 N.W.2d 589 (Mich. 1980).Google Scholar
Ga. Code Ann. § 26-4-140 et seq. (1983).Google Scholar
Alabama, Arkansas, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Minnesota, Missouri, Nebraska, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Washington, West Virginia, Wisconsin, and Wyoming. NCSPAE Report, supra note 4, at 57.Google Scholar
Alabama, California, Connecticut, Illinois, Maine, Oklahoma, and Tennessee. Id. See, e.g., Conn. Gen. Stat. Ann. § 37-1740 (West 1984).Google Scholar
Alabama, Georgia, Oklahoma, and Tennessee. NCSPAE Report, supra note 4, at 56–57. See, e.g., Ala Code § 34-23-115 (1984).Google Scholar
29 U.S.C. §§ 1001–1381 (1982).Google Scholar
Id. § 1144(a).Google Scholar
Id. § 1144(b)(2)(A).Google Scholar
103 S.Ct. 2890 (1983) [hereinafter referred to as Shaw].Google Scholar
567 F. Supp. 1258 (N.D. Ala. 1983) [hereinafter referred to as Peacock].Google Scholar
Id. at 1272-75.Google Scholar
Op. Ga. Att'y Gen. (December 29, 1983) (issued to Johnie Caldwell, State Insurance Commissioner).Google Scholar
GMC, International Union, United Automobile, Aerospace and Agriculture Implement Workers of America v. Caldwell, No. C84-331-A (N.D. Ga., February 21 1984).Google Scholar
Op. Okla. Att'y Gen. (February 1, 1984) (issued to David Riggs, State Representative).Google Scholar
Shaw, supra note 47, at 2901 n. 21.Google Scholar
Braden, Larry, Executive Director of the Georgia Pharmaceutical Association, estimates that it may cost the Association a few hundred thousand dollars to assist the Georgia Attorney General in defending the Georgia TPPP law.Google Scholar
Weekly Pharmacy Reports: “The Green Sheet” 33(9): 2–3 (February 27, 1984).Google Scholar
Klamath-Lake Pharmaceutical Ass'n v. Klamath Medical Serv. Bureau, 701 F.2d 1276,1280-81 (9th Cir. 1983), cert. denied, 104 S.Ct. 88 (1983).Google Scholar
Id. at 1287–88Google Scholar
743 F.2d 1388 (9th Cir. 1984) [hereinafter referred to as DeModena].Google Scholar
15 U.S.C. § 13c. The Nonprofit Institutions Act provides: “Nothing in the [Robinson-Patman Act] shall apply to purchases of supplies for their own use by schools, colleges, universities, public libraries, churches, hospitals, and charitable institutions not operated for profit.”Google Scholar
See Abbott Laboratories v. Portland Retail Druggists Ass'n, 425 U.S. 1 (1976) (discussing the scope of “own use” as applied to nonprofit hospitals reselling prescription drugs) [hereinafter referred to as Abbott Laboratories].Google Scholar
DeModena, , supra note 58, at 1393.Google Scholar
Id. at 1390.Google Scholar
Abbott Laboratories, supra note 60, at 14.Google Scholar
FTC Advisory Opinion Letter to Smith, Irwin S. M.D., President, HCMA (June 7, 1983).Google Scholar
FTC Advisory Opinion Letter to Robert E. Nord (February 24, 1983).Google Scholar
Some examples include the Michigan Pharmacy Network, the Iowa Pharmacy Network, the Missouri Foundation for Pharmaceutical Care, the Kansas Pharmacy Service Corporation and the Florida Pharmacy Plus System.Google Scholar